Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | IDO1 | P14902 | 2/20 | 0.62 |
| ▸ | AGXT | P21549 | 2/20 | 0.62 |
| ▸ | APP | P05067 | 2/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638649 | 0.90 | MAOB (0.65) | MAOBCYP3A4ALDH1A1APPMRGPRX4 | |
| SCHEMBL14854755 | 0.87 | MAOB (0.77) | MAOBIDO1AGXTMRGPRX4TP53 | |
| SCHEMBL9795738 | 0.87 | MAOB (0.70) | MAOBCYP3A4ALDH1A1APPTP53 | |
| SCHEMBL21480309 | 0.85 | MAOB (0.64) | MAOBCYP3A4ALDH1A1MRGPRX4TP53 | |
| SCHEMBL16710547 | 0.84 | MAOB (0.71) | MAOBIDO1AGXTAPPMRGPRX4 | |
| SCHEMBL5090301 | 0.84 | MAOB (0.68) | MAOBIDO1AGXTAPPMRGPRX4 | |
| SCHEMBL4638480 | 0.83 | MAOB (0.70) | MAOBCYP3A4IDO1APPTP53 | |
| SCHEMBL13462942 | 0.83 | MAOB (0.69) | MAOBIDO1AGXTAPPMRGPRX4 | |
| SCHEMBL13263642 | 0.82 | MAOB (0.79) | MAOBIDO1AGXTMRGPRX4TP53 | |
| 3-(Benzyloxy)Aniline SCHEMBL291445 | 0.82 | MAOB (1.00) | MAOBCYP3A4APPTP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230100082-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-30 | — | — | US | disclosed |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-03-16 | — | — | US | disclosed |
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100082-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | MAOB 594/4885CYP3A4 1570/4885ALDH1A1 1220/4885 |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | MAOB 3352/4885CYP3A4 273/4885ALDH1A1 2723/4885 |
| US-20170073314-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | MAOB 621/4885CYP3A4 1447/4885ALDH1A1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.